News und Analysen

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has executed a global licensing collaboration agreement with Novartis to develop and commercialize

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its second quarter 2020 financial results on Tuesday, August 11, 2020, after the markets

Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2020, highlighting revenue growth and financial strength as well as the advancement of the company’s clinical

The MDS Virtual Congress will take place from 12 to 16 September 2020.

Lyon, 30 July 2020 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer

Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its second quarter 2020 financial results after the market

Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, has enhanced its crisis forecasting and planning technology to predict the COVID-19 census for any U.S. hospital on a given

Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies, and Heal, a market leader in transforming healthcare through in-home, comprehensive primary care, today

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that company management will present at BTIG’s Virtual

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2020.

For the second quarter of 2020, worldwide sales

Regulatory News:

Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will

Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2020 fourth quarter and full year on Tuesday, August 25, 2020, at approximately 6:30 a.m. EDT. The

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2020.

Second Quarter 2020 Financial Highlights:

• 
  Revenue grew 34% versus the same

Transaction highlights

· Esperite NV secures an external financing of up to EUR 35 million through further private placements of convertible notes with share subscription warrants attached over a

VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL, PEA/SME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Prävention und Bekämpfung von

Novocure (NASDAQ:NVCR) announced today the recipients of the AACR-Novocure Grants for Tumor Treating Fields Research program. The program represents a joint effort between Novocure and the American

Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2020, increased its 2020 financial guidance for revenues and Adjusted diluted EPS⁽³⁾ and reaffirmed all other components of its

Regulatory News:

VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL, PEA/SME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic

Recordati Rare Diseases announces today that Lancet Diabetes & Endocrinology has published positive results from the Phase III LINC-3 pivotal study of Isturisa®, recently approved for the treatment

Wie Recordati Rare Diseases heute bekannt gibt, hat das Journal Lancet Diabetes & Endocrinology positive Ergebnisse der Phase-III-Zulassungsstudie LINC-3 für Isturisa^® veröffentlicht, das kürzlich

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the start of a global (except for China) Phase 2/3 safety and efficacy clinical study to evaluate a single nucleoside-modified

Agilent Technologies Inc. (NYSE: A) will release third-quarter fiscal year 2020 financial results after the stock market closes on Aug. 18. The company will also host a live webcast of its investor